Serum miR-92a is Elevated in Children and Adults with Obstructive Sleep Apnea.
Biomarkers
Endothelial dysfunction
Micro RNA
Obstructive sleep apnea
Journal
Journal of molecular biomarkers & diagnosis
ISSN: 2155-9929
Titre abrégé: J Mol Biomark Diagn
Pays: United States
ID NLM: 101580370
Informations de publication
Date de publication:
2020
2020
Historique:
entrez:
11
1
2021
pubmed:
12
1
2021
medline:
12
1
2021
Statut:
ppublish
Résumé
Obstructive Sleep Apnea (OSA) is a highly prevalent condition that is associated with several comorbidities including cardiovascular disease (CVD). Recent studies have revealed mixed results as to whether standard OSA therapy reverses CVD in adult patients. Thus, many advocate for earlier recognition of OSA induced CVD, as early as childhood, to prompt treatment antecedent to the onset of irreversible CVD. Here we investigated if the serum level of miR-92a, a known biomarker for CVD, can be used to identify patients with OSA in both children and adults. Consecutive snoring patients undergoing polysomnography were recruited for determination of circulating miR-92a, in addition to inflammatory and metabolic profiles. We assessed whether circulating miR-92a was associated with OSA severity. Using two separate cohorts of adults (n=57) and children (n=13), we report a significant increase in the serum level of miR-92a in patients with severe OSA (p=0.021) and further demonstrate a significant correlation (Spearman rank correlation 0.308, p=0.010) with serum miR-92a levels and the apnea hypopnea index (AHI), a primary measure of OSA severity. Stepwise regression analysis revealed that serum miR-92a levels were independently associated with AHI (ß=0.332, p=0.003), age (ß=0.394, p=0.002) and LDL cholesterol levels (ß=0.368, p=0.004). Our study is the first to establish that miR-92a is a useful biomarker for OSA severity in both children and adults. Given the canonical role of miR-92a on endothelial dysfunction, miR-92a may be useful to identify early onset CVD in OSA patients or stratify patient CVD risk to identify those that may benefit from earlier OSA treatment.
Sections du résumé
BACKGROUND
BACKGROUND
Obstructive Sleep Apnea (OSA) is a highly prevalent condition that is associated with several comorbidities including cardiovascular disease (CVD). Recent studies have revealed mixed results as to whether standard OSA therapy reverses CVD in adult patients. Thus, many advocate for earlier recognition of OSA induced CVD, as early as childhood, to prompt treatment antecedent to the onset of irreversible CVD. Here we investigated if the serum level of miR-92a, a known biomarker for CVD, can be used to identify patients with OSA in both children and adults.
METHODS
METHODS
Consecutive snoring patients undergoing polysomnography were recruited for determination of circulating miR-92a, in addition to inflammatory and metabolic profiles. We assessed whether circulating miR-92a was associated with OSA severity.
RESULTS
RESULTS
Using two separate cohorts of adults (n=57) and children (n=13), we report a significant increase in the serum level of miR-92a in patients with severe OSA (p=0.021) and further demonstrate a significant correlation (Spearman rank correlation 0.308, p=0.010) with serum miR-92a levels and the apnea hypopnea index (AHI), a primary measure of OSA severity. Stepwise regression analysis revealed that serum miR-92a levels were independently associated with AHI (ß=0.332, p=0.003), age (ß=0.394, p=0.002) and LDL cholesterol levels (ß=0.368, p=0.004).
CONCLUSION
CONCLUSIONS
Our study is the first to establish that miR-92a is a useful biomarker for OSA severity in both children and adults. Given the canonical role of miR-92a on endothelial dysfunction, miR-92a may be useful to identify early onset CVD in OSA patients or stratify patient CVD risk to identify those that may benefit from earlier OSA treatment.
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL108735
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL110350
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL125643
Pays : United States
Organisme : NHLBI NIH HHS
ID : R21 HL106567
Pays : United States
Références
Curr Opin Endocrinol Diabetes Obes. 2010 Apr;17(2):161-5
pubmed: 20125003
Sleep Med. 2013 Jun;14(6):526-31
pubmed: 23643649
Circ Res. 2014 Jan 31;114(3):434-43
pubmed: 24255059
Sleep. 2010 Sep;33(9):1177-83
pubmed: 20857864
J Transl Med. 2016 May 20;14(1):143
pubmed: 27197967
J Am Coll Cardiol. 1999 Nov 15;34(6):1744-9
pubmed: 10577565
Am J Respir Crit Care Med. 2001 Jan;163(1):19-25
pubmed: 11208620
J Inflamm (Lond). 2013 Mar 22;10:13
pubmed: 23518041
Am J Respir Crit Care Med. 2006 Apr 15;173(8):910-6
pubmed: 16424443
Circ Res. 2010 Sep 3;107(5):677-84
pubmed: 20595655
Sleep Med Clin. 2007 Sep;2(3):433-444
pubmed: 18769509
Paediatr Respir Rev. 2006 Dec;7(4):247-59
pubmed: 17098639
Chest. 2012 Mar;141(3):682-691
pubmed: 22030801
Circulation. 2011 Aug 2;124(5):633-41
pubmed: 21768538
Mol Biol Rep. 2018 Aug;45(4):497-509
pubmed: 29725814
Chest. 2000 Sep;118(3):580-6
pubmed: 10988175
Respirology. 2015 Aug;20(6):889-95
pubmed: 26073295
N Engl J Med. 2005 Mar 24;352(12):1206-14
pubmed: 15788497
Arterioscler Thromb Vasc Biol. 2012 Apr;32(4):979-87
pubmed: 22267480
PLoS One. 2013 Dec 05;8(12):e80738
pubmed: 24339880
Pediatrics. 2003 Mar;111(3):554-63
pubmed: 12612236
Circ Res. 2014 Jan 31;114(3):399-401
pubmed: 24481837
Am J Respir Crit Care Med. 2005 Dec 1;172(11):1447-51
pubmed: 16141444
Am J Respir Crit Care Med. 1999 May;159(5 Pt 1):1527-32
pubmed: 10228121
Hypertension. 2008 Jan;51(1):84-91
pubmed: 18071053
J Clin Sleep Med. 2017 Mar 15;13(3):479-504
pubmed: 28162150
Pediatr Pulmonol. 1993 Aug;16(2):124-9
pubmed: 8367218
Am J Respir Crit Care Med. 1996 Feb;153(2):866-78
pubmed: 8564147
N Engl J Med. 2000 May 11;342(19):1378-84
pubmed: 10805822
Am J Respir Crit Care Med. 2002 May 1;165(9):1217-39
pubmed: 11991871
Am J Epidemiol. 2013 May 1;177(9):1006-14
pubmed: 23589584
Sleep Med Rev. 2008 Oct;12(5):339-46
pubmed: 18406637
Sleep. 2008 Aug;31(8):1071-8
pubmed: 18714778
Sleep. 2008 Aug;31(8):1079-85
pubmed: 18714779
Circulation. 2007 Nov 13;116(20):2307-14
pubmed: 17967978
Chest. 2012 Jul;142(1):239-245
pubmed: 22796846
Nat Rev Genet. 2004 Jul;5(7):522-31
pubmed: 15211354
JAMA. 2012 Feb 1;307(5):483-90
pubmed: 22253364
Prog Cardiovasc Dis. 2009 Mar-Apr;51(5):416-33
pubmed: 19249448
Am J Cardiol. 2005 Mar 15;95(6):801-4
pubmed: 15757619
Biosci Rep. 2017 Mar 27;37(2):
pubmed: 28213360
Circulation. 2000 Mar 7;101(9):948-54
pubmed: 10704159
Am J Respir Crit Care Med. 2008 May 15;177(10):1142-9
pubmed: 18276939
J Am Soc Nephrol. 2017 Nov;28(11):3251-3261
pubmed: 28696247
N Engl J Med. 2005 Apr 21;352(16):1685-95
pubmed: 15843671
Stroke. 2006 Sep;37(9):2317-21
pubmed: 16888274
Proc Am Thorac Soc. 2008 Feb 15;5(2):242-52
pubmed: 18250218
Nat Rev Mol Cell Biol. 2014 Aug;15(8):509-24
pubmed: 25027649
Int J Obes (Lond). 2006 Jul;30(7):1041-9
pubmed: 16801941
Science. 2009 Jun 26;324(5935):1710-3
pubmed: 19460962
N Engl J Med. 2016 Sep 8;375(10):919-31
pubmed: 27571048
Sleep. 2018 Mar 1;41(3):
pubmed: 29301021
Am J Respir Crit Care Med. 1998 Apr;157(4 Pt 1):1098-103
pubmed: 9563725
Chest. 2011 Feb;139(2):237-238
pubmed: 21285049
Circulation. 2015 Mar 3;131(9):805-14
pubmed: 25550450
Cardiovasc Res. 2012 Mar 15;93(4):633-44
pubmed: 22258631
Lancet Respir Med. 2015 Apr;3(4):310-8
pubmed: 25682233
Sleep. 2009 Jun;32(6):731-6
pubmed: 19544748
Arch Dis Child. 2003 Feb;88(2):139-42
pubmed: 12538317
Pediatrics. 2012 Sep;130(3):576-84
pubmed: 22926173
Sleep Breath. 2011 Dec;15(4):625-31
pubmed: 21063795